ZyVac^® MMR — trusted protection against measles, mumps, and rubella

ZyVac MMR is a freeze dried, live attenuated viral vaccine developed and manufactured by Zydus Lifesciences. The vaccine contains NLT 1000 CCID50 per dose for Edmonston Zagreb strain of live attenuated Measles virus and RA27/3 strain of rubella virus propagated on Human Diploid Cells and NLT 5000 CCID50 per dose for live attenuated Hoshino strain of Mumps virus propagated on Chick Fibroblast Cells. The vaccine is supplied with diluent used for reconstitution of freeze-dried vaccine.

Key Features

• Trivalent Protection: Offers simultaneous immunity against measles, mumps, and rubella in a single vaccine, helping prevent serious complications such as encephalitis, pneumonia, deafness, congenital rubella syndrome, and infertility.
• Proven Immunogenicity: Clinical trials (Phase II & III) conducted in India demonstrated high seroconversion rates.
• Made-in-India Reliability: A trusted indigenous vaccine supporting national immunization programs and individual protection.

Target Population

ZyVac MMR is indicated for children from 9 months of age and older. It is commonly used in routine childhood immunization schedules, with the first dose recommended at 9–12 months and a second dose at 15-18 months and booster at 4–6 years (as per Indian Academy of Paediatrics guidelines) for long-term protection.

Administration

• Dose: Each dose of 0.5 ml after reconstitution with the supplied diluent.
• Route: Subcutaneous injection, typically in the anterolateral thigh (infants/young children) or upper arm (older children/adults).
• Schedule: Single dose provides initial protection; a booster dose is advised as per national or paediatric immunization guidelines.
• Presentation: Approved in two presentations
• Single dose vial: Use immediately after reconstitution
• Multidose vial (10 doses) : Use within 6 hours after reconstitution.

Store at 2°C to 8°C before and after reconstitution. Protect from light.

Safety and Efficacy

ZyVac MMR has been evaluated in multiple clinical studies involving hundreds of healthy paediatric subjects. It is well tolerated with a favourable safety profile. Common side effects are mild and transient, including injection site redness, swelling, pain, low-grade fever, or mild rash — similar to other MMR vaccines. It is contraindicated in individuals with known hypersensitivity to any component of vaccine (including gelatin, egg protein, cow milk) or those with severe immunosuppression. pregnancy should be avoided for 1 month following vaccination.

As a reliable, high-quality MMR vaccine from Zydus Lifesciences, ZyVac MMR contributes to the elimination of measles and rubella while protecting children from mumps. Vaccination remains one of the most effective public health measures against these vaccine-preventable diseases.

Publications

• Sood A, Mitra M, Joshi HA, Nayak US, Siddaiah P, Babu TR, Mahapatro S, Sanmukhani J, Gupta G, Mittal R, Glueck R. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial. Hum Vaccin Immunother. 2017 Jul 3;13(7):1523-1530. doi: 10.1080/21645515.2017.1302629. Epub 2017 Mar 31. PMID: 28362563; PMCID: PMC5512778.